• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Antibiotics >Cost Reduction of Inhaled Tobramycin by Use of Preservative-Free Intravenous Tobramycin Given via Inhalation
【24h】

Cost Reduction of Inhaled Tobramycin by Use of Preservative-Free Intravenous Tobramycin Given via Inhalation

机译：通过吸入给予无防腐剂的静脉内妥布霉素降低吸入妥布霉素的成本

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study evaluates drug cost outcomes related to automatic therapeutic substitution of branded tobramycin solution for inhalation (TOBI®) with inhaled generic preservative-free intravenous tobramycin (PFIT). A retrospective single-center evaluation of inhaled tobramycin use from 2008 through 2012 was performed. Number of doses dispensed and acquisition costs were obtained. Hourly wage data was acquired, pharmacy production costs were estimated and total cost-savings calculated. Days of therapy (DOTs) were determined for each year. Quality assurance and safety data was collected. In 2008, TOBI® drug costs and doses dispensed were $118,665 and 1769, respectively. Following implementation of the interchange in May 2009, TOBI® utilization ceased. PFIT costs in 2010 through 2012 averaged $34,775 annually and TOBI® cost-avoidance exceeded $94,000 annually when accounting for pharmacy production costs, which were determined to be at most $5.28 per dose. The maximum estimated pharmacy production cost ranged from $8812 to $11,299 annually. PFIT doses dispensed exceeded 1650 each year and annual DOTs ranged from 815 to 1069. The 40-month savings were calculated to be $374,706. Quality assurance and safety data identified one patient who refused PFIT due to odor complaints and one patient who was inappropriately administered a dose orally. Therapeutic substitution of TOBI® with PFIT can produce immediate and sustained savings with an acceptable safety profile.
机译：这项研究评估了与使用吸入的无防腐剂的静脉注射妥布霉素（PFIT）的品牌妥布霉素溶液自动替代吸入疗法（TOBI ®）有关的药物成本结果。对2008年至2012年吸入妥布霉素的使用进行了回顾性单中心评估。获得的剂量数量和获得成本。获取了小时工资数据，估算了药品生产成本，并计算了总成本节省。每年确定治疗天数（DOT）。收集了质量保证和安全数据。 2008年，TOBI ®的药品成本和分配的剂量分别为118,665美元和1769美元。在2009年5月实施互换之后，TOBI ®的使用就停止了。在计算药房生产成本时，2010年至2012年的PFIT成本平均每年为$ 34,775，而TOBI ®避免的成本每年超过$ 94,000，确定每剂最高为$ 5.28。每年药房生产的最高估计成本为8812美元至11299美元。每年分配的PFIT剂量超过1650，每年的DOT从815到1069不等。计算得出的40个月节省为374,706美元。质量保证和安全数据确定了一名因气味投诉而拒绝PFIT的患者和一名口服剂量不当的患者。用PFIT治疗性替代TOBI ®可以立即产生持续的节省，并具有可接受的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号